A5102834751- Inflammatory mediators and NSAID effects
- Osteoarthritis Treatment and Mechanisms
- Rheumatoid Arthritis Research and Therapies
- Pain Mechanisms and Treatments
- Anesthesia and Pain Management
- Glioma Diagnosis and Treatment
- Spine and Intervertebral Disc Pathology
- Total Knee Arthroplasty Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Reconstructive Surgery and Microvascular Techniques
- Neuroblastoma Research and Treatments
- Shoulder Injury and Treatment
- Sports injuries and prevention
- Knee injuries and reconstruction techniques
- Ear and Head Tumors
- Cancer Treatment and Pharmacology
- Ear Surgery and Otitis Media
- Radiopharmaceutical Chemistry and Applications
- Facial Nerve Paralysis Treatment and Research
- History of Medical Practice
- Orthopedic Surgery and Rehabilitation
- Musculoskeletal pain and rehabilitation
- Acute Myeloid Leukemia Research
- Sexual function and dysfunction studies
- Pain Management and Opioid Use
Pfizer (United States)
2013-2023
Cassava Sciences (United States)
2008
Johns Hopkins University
1997-2006
Northwestern University
2005
Johns Hopkins Medicine
1999
Duke University
1993-1998
Memorial Sloan Kettering Cancer Center
1997
The University of Texas Southwestern Medical Center
1997
University of Toronto
1997
Sunnybrook Health Science Centre
1997
Valdecoxib and its intravenous prodrug parecoxib are used to treat postoperative pain but may involve risk after coronary-artery bypass grafting (CABG). We conducted a randomized trial assess the safety of these drugs CABG.In this randomized, double-blind study involving 10 days treatment 30 follow-up, 1671 patients were randomly assigned receive for at least 3 days, followed by oral valdecoxib through day 10; placebo valdecoxib; or days. All had access standard opioid medications. The...
Anterior cruciate ligament (ACL) rupture is a common debilitating injury that can cause instability of the knee. We aimed to investigate best management strategy between reconstructive surgery and non-surgical treatment for patients with non-acute ACL persistent symptoms instability.We did pragmatic, multicentre, superiority, randomised controlled trial in 29 secondary care National Health Service orthopaedic units UK. Patients symptomatic knee problems (instability) consistent an were...
PURPOSE To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses this treatment. METHODS In phase I trial, eligible were treated a single injection 131I-labeled 81C6. Cohorts three six escalating dosages 131I (starting 20 mCi 20-mCi escalation subsequent cohorts) administered through an Ommaya reservoir SCRC. Patients followed up...
Valdecoxib and its intravenous prodrug parecoxib are reported to increase thromboembolic risk after coronary artery bypass grafting. The authors conducted a randomized trial examine their safety analgesic efficacy in patients recovering from major noncardiac surgical procedures.The was double-blind, with 10 days of treatment 30 follow-up. Patients (n = 1,062) received either parenteral for 3 oral valdecoxib the rest period or placebo medications throughout. frequency predefined adjudicated...
Objective To evaluate whether subjects with knee or hip osteoarthritis (OA) pain on non-steroidal anti-inflammatory drugs (NSAIDs) received greater benefit when tanezumab monotherapy replaced was coadministered NSAIDs. Methods Subjects (N=2700) intravenous (5 10 mg) placebo every 8 weeks without oral naproxen 500 mg twice daily celecoxib 100 daily. Efficacy assessed as change from baseline to week 16 in three co-primary endpoints: Western Ontario and McMaster Universities Osteoarthritis...
Tanezumab is a humanized monoclonal antinerve growth factor antibody in development for treatment of chronic pain. In phase III, placebo- and active-controlled study, we investigated the efficacy safety tanezumab osteoarthritis (OA) hip or knee Patients (N=610) received up to 2 doses intravenous (5 10mg 8-week intervals), controlled-release oral oxycodone (10 40 mg every 12 hours), placebo. The primary endpoint was mean change from baseline week 8 Western Ontario McMaster Universities...
Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy safety of tanezumab added oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain.Patients (N=604) moderate severe OA tolerating stable DSR were randomised treated 75 mg twice daily combined intravenous 10, 5 2.5 placebo at weeks 0, 8 16. Co-primary endpoints (Western...
Objective. Two studies evaluated efficacy and safety of tanezumab versus naproxen for treatment knee or hip osteoarthritis (OA). Methods. Randomized controlled [ NCT00830063 (Study 1015, n = 828) NCT00863304 1018, 840)] subjects with OA compared intravenous (5 mg 10 mg) to placebo (500 twice daily). Coprimary outcomes were Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) Pain, WOMAC Physical Function (0–10 numerical rating scale), patient’s global assessment at Week 16....
To assess the long-term safety and 16-week efficacy of subcutaneous tanezumab in patients with hip or knee osteoarthritis (OA).This was a phase III randomized, double-blind, active treatment-controlled (using nonsteroidal antiinflammatory drugs [NSAIDs] as treatment control) trial (56-week treatment/24-week posttreatment follow-up) adults who were receiving stable-dose NSAID therapy at time screening had Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) pain physical...
Abstract Background This phase III, randomized, double-blind, placebo-controlled, parallel-group study assessed the efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy. Methods Subjects were randomized (stratified by (1) tumor aggressiveness (2) presence/absence concomitant anticancer treatment) placebo or 20 mg. Treatment was administered subcutaneous injection every 8 weeks for 24 (3 doses) followed a...
The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied six patients. Primary lesions were reduced by 80% or more on contrast-enhancing cross-sectional area four patients a lesser extent two others after cycles chemotherapy. lesion sites demonstrated no contrast enhancement three who completed therapy. However, concurrent with response at disease sites, multiple...
A noncontrolled, randomized, multicenter study (NCT00924664) evaluated long-term safety and effectiveness of tanezumab in patients with chronic low back pain following a randomized placebo- active-controlled parent that analgesic efficacy. Patients were to 10mg (n=321) or 20mg (n=527) administered at 8-week intervals via 3 intravenous injections followed by 4 subcutaneous injections. Effectiveness analyses included change from baseline Brief Pain Inventory Short Form, Roland Morris...
A pooled analysis was conducted to evaluate tanezumab efficacy and safety in patients with osteoarthritis (OA), including subgroup analyses of at-risk diabetes, severe OA symptoms, those aged ≥65 years.Data from phase III placebo-controlled clinical trials moderate-to-severe the knee or hip were (four trials) (nine trials). Patients received intravenous tanezumab, plus an oral NSAID (naproxen, celecoxib, diclofenac), active comparator diclofenac, oxycodone), placebo. Efficacy assessments...
Sexual side-effects due to antidepressant treatment are an important consideration when selecting a regimen and can influence patient compliance. function during with the selective noradrenaline reuptake inhibitor reboxetine, serotonin (SSRI) fluoxetine placebo has been assessed in multicentre, randomized, 8-week, double-blind study of 450 patients diagnosed major depressive disorder. was measured by Rush Inventory completed male female administered at baseline, week 4 8. The results...
Objective: To investigate the effects of virulence characteristics specific pneumococcal proteins on inner ear.Main Outcome Measures: A histologic comparison inflammatory cell infiltration and pathologic changes in round window membrane ear.Results: Most animals inoculated with highdose pneumolysin or wild-type bacteria showed severe ears.The ears most surface protein antigen A-deficient appeared normal.Conclusions: Pneumococcal are 2 important factors ear damage secondary to otitis...
The objective of this study was to investigate the safety and efficacy subcutaneous (SC) intravenous (IV) tanezumab administration in osteoarthritis (OA) patients.Study 1027 (NCT01089725), a placebo-controlled trial, evaluated SC (ie, 2.5, 5, 10 mg) therapeutic equivalence mg given subcutaneously versus intravenously every 8 weeks symptomatic treatment OA. Coprimary endpoints were: change from baseline Western Ontario McMaster Universities Osteoarthritis index (WOMAC) Pain Physical Function...
Although pilocytic astrocytomas (PA) generally are considered benign, a subset of patients with PA have disease progression despite standard treatment surgery and radiation therapy. The authors report their experience chemotherapy in this patient group.The treated 11 (4 males 7 females; median age at diagnosis, 8 years) pathologically confirmed chemotherapy. In eight patients, tumor or recurrence prior therapy led to treatment. three children younger than 5 years, was given lieu immediately...
This study was designed to evaluate strategies overcome the resistance of anaplastic gliomas brain external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were > or = 15 years age, had a histologic diagnosis malignant glioma, and Karnofsky performance status (KPS) 60%. In Randomization 1, patients assigned receive either ERT alone (61.2 Gy) mitomycin C (Mito, IV 12.5 mg/m(2)) during first fourth week ERT. After this treatment, went on 2, where they BCNU (i.v. 200 given at 6-week...
To quantitate the functional morbidity to hand and wrist due harvest of a radial forearm free fasciocutaneous flap.Case-control study with age-matched control groups.Tertiary care hospital.A consecutive sample 21 patients who underwent flap reconstruction head neck from June 1993 February 1995 constitute experimental group. Thirteen those eligible participated in study. Two groups were identified. One cohort included 13 cancer tissue transfer other than flap. The consisted 16 subjects...